Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

694 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Delivery of a BET protein degrader via a CEACAM6-targeted antibody-drug conjugate inhibits tumour growth in pancreatic cancer models.
Nakazawa Y, Miyano M, Tsukamoto S, Kogai H, Yamamoto A, Iso K, Inoue S, Yamane Y, Yabe Y, Umihara H, Taguchi J, Akagi T, Yamaguchi A, Koga M, Toshimitsu K, Hirayama T, Mukai Y, Machinaga A. Nakazawa Y, et al. Among authors: yamane y. Nat Commun. 2024 Mar 11;15(1):2192. doi: 10.1038/s41467-024-46167-1. Nat Commun. 2024. PMID: 38467634 Free PMC article.
ER-851, a Novel Selective Inhibitor of AXL, Overcomes Resistance to Antimitotic Drugs.
Tsukamoto S, Sugi NH, Nishibata K, Nakazawa Y, Ito D, Fukushima S, Nakagawa T, Ichikawa K, Kato Y, Kakiuchi D, Goto A, Itoh-Yagi M, Aota T, Inoue S, Yamane Y, Murai N, Azuma H, Nagao S, Sasai K, Akagi T, Imai T, Matsui J, Matsushima T. Tsukamoto S, et al. Among authors: yamane y. Mol Cancer Ther. 2023 Jan 3;22(1):12-24. doi: 10.1158/1535-7163.MCT-21-0879. Mol Cancer Ther. 2023. PMID: 36279567
Discovery of a potent and selective Axl inhibitor in preclinical model.
Inoue S, Yamane Y, Tsukamoto S, Azuma H, Nagao S, Murai N, Nishibata K, Fukushima S, Ichikawa K, Nakagawa T, Hata Sugi N, Ito D, Kato Y, Goto A, Kakiuchi D, Ueno T, Matsui J, Matsushima T. Inoue S, et al. Among authors: yamane y. Bioorg Med Chem. 2021 Jun 1;39:116137. doi: 10.1016/j.bmc.2021.116137. Epub 2021 Apr 21. Bioorg Med Chem. 2021. PMID: 33930844
Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors.
Inoue S, Yamane Y, Tsukamoto S, Murai N, Azuma H, Nagao S, Nishibata K, Fukushima S, Ichikawa K, Nakagawa T, Hata Sugi N, Ito D, Kato Y, Goto A, Kakiuchi D, Ueno T, Matsui J, Matsushima T. Inoue S, et al. Among authors: yamane y. Bioorg Med Chem Lett. 2021 Sep 15;48:128247. doi: 10.1016/j.bmcl.2021.128247. Epub 2021 Jul 13. Bioorg Med Chem Lett. 2021. PMID: 34271070
Microregional antitumor activity of a small-molecule hypoxia-inducible factor 1 inhibitor.
Okamoto K, Ito D, Miyazaki K, Watanabe S, Tohyama O, Yokoi A, Ozawa Y, Asano M, Kawamura T, Yamane Y, Nagao S, Funasaka S, Kamata J, Kotake Y, Aoki M, Tsukahara N, Mizui Y, Tanaka I, Sawada K. Okamoto K, et al. Among authors: yamane y. Int J Mol Med. 2012 Apr;29(4):541-9. doi: 10.3892/ijmm.2011.875. Epub 2011 Dec 29. Int J Mol Med. 2012. PMID: 22211243 Free PMC article.
E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models.
Watanabe Miyano S, Yamamoto Y, Kodama K, Miyajima Y, Mikamoto M, Nakagawa T, Kuramochi H, Funasaka S, Nagao S, Sugi NH, Okamoto K, Minoshima Y, Nakatani Y, Karoji Y, Ohashi I, Yamane Y, Okada T, Matsushima T, Matsui J, Iwata M, Uenaka T, Tsuruoka A. Watanabe Miyano S, et al. Among authors: yamane y. Mol Cancer Ther. 2016 Nov;15(11):2630-2639. doi: 10.1158/1535-7163.MCT-16-0261. Epub 2016 Aug 17. Mol Cancer Ther. 2016. PMID: 27535969
694 results